Proceeding contribution from Lord Lansley (Conservative) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
: We have not heard the hon. Lady’s proposal on Herceptin. On the face of it, Herceptin has significant beneficial effects as disclosed in clinical trials, but a licence application has yet to be made in respect of it. In France, there is explicit recognition that in certain circumstances, certain drugs can provisionally be made available for use, pending licensing and approval. Is that not the right mechanism? If not, what does the hon. Lady propose?
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1033
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:37 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285112
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285112
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285112